Freeline Announces First Patient Dosed in the Phase 1/2 B-LIEVE Dose-Confirmation Trial in Hemophilia B
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
FRLN
Freeline Therapeutics Holdings plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2020
Get push alerts for FRLN
Full FRLN profile on Quantisnow Follow FRLN and get a push notification the moment its next story breaks.